switching from tirzepatide to zepbound (tirzepatide) superior Wegovy (semaglutide), says Lilly-funded clinical trial Zepbound® | GLP-1/GIP Treatments

Our compassionate providers offer personalized guidance and ongoing support, helping you implement these lifestyle adjustments consistently, patiently, and persistently

Additionally, high priority measures are included in our data submission requirements for traditional MIPS as clinicians must submit collected data for at least 6 quality measures (including one outcome measure or high priority measure in the absence of an applicable outcome measure), or a complete specialty measure set

Inflammasomemediated innate immunity in Alzheimer's disease

Random start using birth control pills: Birth control suppresses the ovaries, which means that it prevents the ovaries from growing a follicle and allows the start of treatment to be much more flexible

Tirzepatide (Mounjaro for diabetes and Zepbound for obesity, both Eli Lilly), a dual GLP-1/GIP agonist titrated gradually across a broad dosing range, showed a favorable safety profile, with GIP agonism probably buffering GLP-1-mediated fluid shifts, stabilizing vascular tone and reducing ischemic vulnerability